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PCommentary
Echocardiography for Cardiac
Resynchronization Therapy Selection
Fatally Flawed or Misjudged?
John E. Sanderson, MD
Birmingham, United Kingdom
After the publication of the PROSPECT (Predictors of Response to CRT) trial, the use of echocardiography for the
assessment of mechanical dyssynchrony and as a possible aid for selecting patients for cardiac resynchroniza-
tion therapy has been heavily criticized. Calls have been made to observe the current guidelines and implant
according to the entry criteria of recent major trials. However, although this approach is currently to be recom-
mended, the attempt to identify patients who will not receive the benefits of cardiac resynchronization therapy
and whose clinical condition may be worsened should continue. Devices are not analogous to drugs: initial costs
are higher, complications are significant, and the device cannot readily be withdrawn. Professional resources
and the costs to society are high and wasted if devices are implanted inappropriately. Rather that discarding
the attempt to identify the most suitable patients pre-operatively, further work is needed to refine the tech-
niques and new clinical trials performed. A combination of methods that include finding the site of latest
mechanical activation, myocardial scar localization, and assessing venous anatomy pre-operatively may
help to identify those who will not derive any benefit or be potentially worsened. (J Am Coll Cardiol 2009;
53:1960–4) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.12.071n
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Hithout doubt cardiac resynchronization therapy (CRT) is
ood treatment for patients with heart failure (1). The
enefits of CRT are similar in magnitude to those seen with
ngiotensin-converting enzyme (ACE) inhibitors and beta-
lockers, and they are incremental to the benefits of medical
herapy. However, though the implant success rate is about
5%, there are complications: 4.3% of patients develop
echanical problems, and there is a 0.3% to 0.5% risk of
eath and a 1% to 2% risk of wound or device infection (1).
y 11 months, lead problems requiring intervention occur
n about 7% of patients. Furthermore, in earlier trials, a
onsistent feature was that about one-third of the patients
id not appear to respond clinically or in terms of echocar-
iographic measured ventricular volumes (2–4). Indeed, it is
well-recognized clinical observation that CRT does not
ork in all patients and, indeed, may worsen heart failure in
few. In the recent PROSPECT (Predictors of Response to
RT) trial, the clinical composite response was unchanged
n 50% and actually worsened in 16%, 35% had a 15%
eduction in left ventricular (LV) end-systolic volume, and
n 9%, LV volumes actually increased by more than 15% (5).
herefore, CRT can apparently worsen heart failure in
ome patients, probably by inducing dyssynchrony where
rom the Department of Cardiovascular Medicine, University of Birmingham,
irmingham, United Kingdom.d
Manuscript received November 10, 2008; revised manuscript received December 8,
008, accepted December 18, 2008.one existed before. It would appear reasonable to try to
dentify patients more accurately before implantation. One
ay is to use echocardiography to measure mechanical
yssynchrony, which, theoretically, it is well-suited to do.
ubsequently, a large number of studies were performed
sing various echocardiographic indexes, many of which
ppeared to be able to predict clinical responders from
onresponders. This approach, however, has been criticized
ince the publication of the PROSPECT trial (5), and in
his issue of the Journal, Hawkins et al. (6) have written
nother highly critical review of this approach to CRT
election. However, although they claim that the echocar-
iographic approach to assess mechanical dyssynchrony is
atally flawed, their arguments are weakened by several
nsubstantiated comments. For example, they claim that
many clinicians have rejected international guidelines in
avor of echocardiographic selection criteria.” The evidence
or this allegation is absent, and it is extremely unlikely that
ny hospital in the U.S. or Europe is deliberately ignoring
ecommended guidelines and implanting or denying im-
lants on the basis of echocardiographic measurements
lone. But a fundamental issue in this debate is whether
linical response matters at all.
o Nonresponders Matter?
awkins et al. (6) state, “Response is itself a flawed
ichotomy. All medical therapies present a continuous
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May 26, 2009:1960–4 Echocardiography for CRT Selectionpectrum ranging from harm to benefit” and “On the basis
f the evidence in populations, we prescribe ACE inhibitors
or all patients with heart failure. We do not dwell on
electing which patients will benefit. The arguments apply
qually to drugs and devices” (6). But do they? This is wrong
n at least 2 counts. First, devices are different from drugs:
he up-front costs are higher for the device and the
mplantation procedure, the initial complications are poten-
ially greater (infection, coronary sinus dissection, and so
n), and a device is much more difficult to remove than a
rug to stop. Most clinicians would not equate an expensive
evice with a drug, and this view was recently endorsed in
nother editorial (7). Second, one of the major develop-
ents in current pharmacotherapy is directed at exactly the
roblem of identifying those patients who are most likely to
enefit and least likely to have side effects—so-called “tai-
ored or individualized therapy.” Pharmacogenomics has the
ame aim. Also, in most major drug trials in heart failure,
atients were excluded from entry if they had already
xperienced an adverse effect with the study drug, which
annot be done with devices.
Hawkins et al. (6) also imply that patients who worsen
linically may still benefit. However, this seems highly
nlikely. All of the successful medical therapies in heart
ailure that have reduced mortality have also shown some
egree of improvement in symptoms, LV volumes, and
everse remodeling, as seen with beta-blockers, ACE inhib-
tors, and aldosterone antagonists (8). Furthermore, the
ame seems to be true for CRT. Recently Kronberg et al. (9)
ublished long-term follow-up data of 179 patients who
ad CRT or a CRT defibrillator implanted with a mean left
entricular ejection fraction (LVEF) of 22.5% and a mean
RS duration of 176 ms. Mortality at 5 years was 53%. In
oth univariate and multivariate analysis, a lack of improve-
ent in New York Heart Association (NYHA) functional
lass was the strongest predictor of mortality. QRS short-
ning was unrelated to mortality. Cha et al. (10) from the
ayo Clinic also published their results of 309 patients who
eceived CRT of which 174 returned for follow-up and 127
ad repeat echocardiography. The baseline clinical charac-
eristics and survival were similar among those who did or
id not return for follow-up. Survival after CRT was
ssociated with a decrease in NYHA functional class (risk
atio: 0.43, p  0.0004) and an increase in the ejection
raction (risk ratio: 0.94, p  0.02). Change in ejection
raction and NYHA functional class were correlated, and
djusting for this covariance, a change in NYHA functional
lass was associated with improved survival. They concluded
hat patients who experienced improved symptoms, ventric-
lar function, and/or hemodynamics have a better survival
fter CRT. In a recent study, Ypenburg et al. (11) found
hat in 302 CRT patients more reverse remodeling resulted
n less heart failure hospitalizations and lower mortality during
ong-term follow-up. The negative responder group had a
arkedly lower survival rate. These data, therefore, strongly
uggest that mortality is related to symptomatic and hemo- yynamic improvement. It seems
ighly unlikely that, given all of
he other work in heart failure, if a
reatment causes symptoms to de-
eriorate, LV volumes to increase,
nd ejection fractions to decline it
ill show a mortality benefit.
The argument, therefore, that
rying to identify nonresponders
s a worthless exercise appears
xtreme. To most, common sense
uggests that implanting a device
nto patients who will gain no
linical benefit or are even made
orse is not likely to be fruitful
r cost-effective. It is interesting
hat the largest randomized mor-
ality trial of CRT—the CARE-HF (Cardiac Resynchro-
ization Heart Failure) study (12)—has not published so far
ny data on the percentage of clinical responders or nonre-
ponders, even though NYHA functional class and quality
f life were documented in this study. However, analysis of
he results shows that all patients were in NYHA functional
lass III or IV at baseline as required for entry, and by the
8-month follow-up period, 152 patients in the medical
herapy group were still in NYHA functional class III/IV,
ut interestingly, so were 80 patients who received CRT. It
s not known whether these patients, whose NYHA func-
ional class did not improve, received any mortality benefit
r not. Also there has been no published data on the relation
f outcome to changes in NYHA functional class or quality
f life. In addition, there is a cost implication of nonre-
ponders. Hawkins et al. (6) state that “Unlike drugs, the
ajority of the lifetime cost for devices is incurred at
mplantation. Identifying so-called ‘nonresponders’ is there-
ore attractive to governments, health services, and other
ayers.” But the obvious corollary is that identifying non-
esponders is probably not attractive to the device industry
ither, as lower number of devices will be implanted. This
bvious converse argument is not heard very often. (All of
he clinical trials of CRT, including the PROSPECT trial,
ave been funded by device companies.) However, the cost
f not identifying nonresponders to society as a whole is
robably very high.
hat Is the Potential Cost of Nonresponders?
eft bundle branch block (LBBB) has been the main criteria
or selecting patients for CRT as recommended in the
uidelines. LBBB, though, is present in about 25% of the
eneral heart failure population (13) and in 35% of patients
ith more severe LV systolic dysfunction, typical of patients
ho might be considered for CRT. In Europe, the esti-
ated heart failure prevalence is 2% to 2.5% overall (14).
he yearly incidence of heart failure in persons age 55
Abbreviations
and Acronyms
ACE  angiotensin-
converting enzyme
CRT  cardiac
resynchronization therapy
LBBB  left bundle branch
block
LV  left ventricle/
ventricular
LVEF  left ventricular
ejection fraction
NYHA  New York Heart
Association
TDI  tissue Doppler
imagingears is 15 per 1,000 of the population. One in 3 persons age
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Echocardiography for CRT Selection May 26, 2009:1960–455 years will develop heart failure. Currently, up to 14
illion people in Europe have heart failure. Therefore,
ossibly there are 5 million people with heart failure and
BBB in Europe. Of these potential 5 million candidates
or CRT (i.e., that have heart failure and LBBB) in Europe,
0% may well turn out to be nonresponders, which is about
.5 million people. At a conservative estimate of €5,000 per
evice, this equals €7.5 billion, which could be a complete
aste of money. In addition, these 1.5 million nonre-
ponders would have a risk of death at time of implantation
f 0.5%, which of 1.5 million nonresponders approximates
o 22,500 people. It is possible, therefore, 22,500 people in
urope could die at the time of implantation during a
rocedure that would have given them no possible clinical
enefit in terms of symptoms or functional improvement.
n top, we could add in the risk of infection, removal of the
ystem, and coronary dissection complications, which were
ound in 2.4% of all patients in the CARE-HF study. The
gures for the U.S. are likely to be similar although costs
ill be higher. Therefore, the argument in favor of identi-
ying nonresponders is powerful, not only to prevent unnec-
ssary harm to patients but also because of the considerable
aste of financial and medical resources.
easons for Lack of Clinical Response
t is obvious that multiple reasons may account for a poor
linical response, which will vary from individual to indi-
idual. These include the lack of correctable mechanical
yssynchrony, a poor lead position (not positioned at the
ite of latest activation), the presence of a lateral wall
yocardial scar, dislodgement, and suboptimal pacemaker
ettings for interventricular timing and atrioventricular in-
ervals. Although Hawkins et al. (6) extol the usefulness of
he simple electrocardiogram (ECG), they appear to con-
use the effects of electrical and mechanical dyssynchrony.
y many measures the ECG is a poor indicator of mechan-
cal dyssynchrony; although a very wide QRS is commonly
ssociated with mechanical dyssynchrony, this is not always
he case (15,16), which is not surprising given the very
ariable nature of activation in LBBB (17). However, there
s evidence that CRT is beneficial in those with mechanical
ut no electrical dyssynchrony (narrow QRS) (18), despite
he results of the RethinQ (Cardiac Resynchronization
herapy in Patients with Heart Failure and Narrow QRS)
tudy (19). Whether CRT is beneficial in those with
lectrical dyssynchrony (wide QRS) but no mechanical
yssynchrony is at present unknown. But in experimental
tudies, improvement after CRT in both wide and narrow
RS situations is closely related to reduced mechanical
yssynchrony (20). As Abraham and Abraham (20) con-
lude in a recent editorial, “ample data suggests that
echanical dyssynchrony is likely a critical substrate for
RT efficacy.” Even the CARE-HF trial investigators have
hown that the main predictors of response to CRT were
ystolic blood pressure and interventricular mechanical delay cut not the ECG or QRS duration (21). Further evidence
or the important role of mechanical dyssynchrony comes
rom recent studies that have correlated the site of maximal
yssynchrony and the pacing site (22,23). These studies
ave shown that the closer that pacing is performed to the
ite of maximal dyssynchrony, the greater benefit to the
atient with better clinical outcomes (mortality and heart
ailure hospitalizations). Thus, identifying mechanical dys-
ynchrony is likely to be much more profitable than iden-
ifying an electrical phenomenon alone, particularly when it
s based on a surface ECG. Hawkins et al. (6) have
horoughly reviewed, but are very critical about, the many
arly echocardiographic studies that attempted to identify
redictors, but, in fairness, none were designed to be major
utcome trials but were exploratory in nature. However, the
ajor impediment to the acceptance of this concept has
een the publication of the PROSPECT trial (5) results.
owever, the PROSPECT trial has major flaws such that it
s effectively a study of laboratory error rather than a test of
hypothesis.
esign of the PROSPECT Trial
his was a prospective, multicenter, nonrandomized trial
nvolving 53 centers in the U.S., Europe, and Hong Kong,
nd 498 subjects with standard indications for CRT were
nrolled. Twelve echocardiographic parameters of dyssyn-
hrony based on both conventional and tissue Doppler
ethods were evaluated. An improved clinical composite
core and a reduction in LV end-systolic volume 15% at 6
onths was considered to be a positive response to CRT.
he main outcome was that clinical composite score was
mproved in 69% of 426 patients, and LV end-systolic
olume decreased 15% in 56% of 286 patients with paired
ata. The ability of the 12 echocardiographic parameters to
redict either clinical composite score or the LV end-
ystolic volume responses was poor; sensitivity ranged from
% to 77% and specificity from 31% to 93%. All of the
arameters tested had an area under the receiver-operating
haracteristics curve of 0.62. In addition, there appeared
o be a great variability in analysis of dyssynchrony param-
ters. After this disappointing result, the use of echocardi-
graphy or any method for assessing mechanical dyssyn-
hrony has been largely dismissed for the reasons given by
awkins et al. (6). Is this response justified based on this
rial?
nalysis of the PROSPECT Trial Results
he interobserver coefficient of variation for dyssynchrony
easurements varied from 32% to 72%. The intraoperator
oefficient of variation varied from 16% to 24%. Of course
his may just reflect the general difficulty of the tissue
oppler imaging (TDI) methodology. However, the vari-
bility of interobserver coefficient of variation for the mea-
urement of end-systolic volume was 14.5%. This raises
oncerns that the problem was more with the quality of
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May 26, 2009:1960–4 Echocardiography for CRT Selectionchocardiography in these centers. This was reinforced by
he fact that the centers reported the mean LVEF to be
3.6  7% but the core laboratory measured mean LVEF
as 29.3  10%; in fact, 20.2% of the subjects had a core
aboratory measured LVEF 35% and should not, there-
ore, have been included in the study according to the entry
equirements.
There were further problems with image quality. One-
hird of the images could not be analyzed even for LV
nd-systolic volume. In fact, only 286 of 426 patients had
he volumes measured. There were no effective measures
rom the echocardiography core laboratory for echocardiog-
aphy quality control throughout the study, and this may
ell have impacted the results of the other centers despite
ome initial training. Third, there was a problem with
ultiple echocardiographic machines; 37% of machines
ere GE manufactured, 50% were Philips, and 12% were
iemens. Forty percent were old machines incapable of
cquiring good quality color-coded TDI images, and, un-
urprisingly, they failed in the offline analysis. More impor-
antly, all TDI data from the Siemens’ machines were
xcluded because of suboptimal images. It also needs to be
emembered that the previously published data are vendor
pecific.
ite Selection
nother important factor was that the sites were selected
ecause they were high-volume implantation sites. They
ere selected, therefore, on their CRT experience, not
chocardiographic experience. The availability of the appro-
riate echocardiography equipment and echocardiographic
xpertise, TDI and dyssynchrony assessment, was appar-
ntly overlooked. This study was, of course, funded by a
evice manufacturer, and the sites were selected by the
evice company. Echocardiography training was minimal
nd consisted of 1 day, which clearly would be inadequate
or TDI analysis. A learning curve for CRT implantation is
ell recognized, but there is also a learning curve for
chocardiographic assessment of dyssynchrony in both
nowledge and techniques. The 3 echocardiography core
aboratories were also pre-selected by the manufacturer that
ponsored the study. They had a limited track record for
ublications on TDI. Therefore, is the reported variability
or the measurements really reflecting the variability of the
echnical and analytical skill of the echocardiography centers
ather than the measurements per se? However, the vari-
bility of the measurements was reported as a failure of
chocardiography techniques. TDI patterns are variable and
an be difficult to interpret, and, indeed, examples have been
hown in recent publications to illustrate the unreliability of
DI. However, by moving the cursor around the ventricle
nd adding in other techniques such as strain, it can be
ossible to identify which is the correct systolic peak in the
ajority of patients.Thus, the PROSPECT study was a nonrandomized
tudy, which assessed too many echocardiographic param-
ters, was funded by a device company, and had center
election based on implantation volumes rather than echo-
ardiography track record. Consequently, there must be
erious concerns about the quality control of the echocardi-
graphy laboratories in these centers. This trial is not
ufficient grounds to discard the whole attempt to measure
echanical dyssynchrony. Future multicenter trials that
ttempt to identify nonresponders using echocardiography
efore implantation need to recognize not only the impor-
ance of device implantation training but also that the same
tandards of expertise and training should apply to the
chocardiographic assessment of dyssynchrony with signif-
cant periods of hands-on training.
However, without a doubt there are technological and
ethodological problems with current echocardiography
echniques, which Hawkins et al. (6) have thoroughly
ighlighted, but new echocardiographic developments are
ccurring. TDI does have limitations: angle dependency,
ormal segments are affected by tethering from adjacent
egments (due to scar or ischemia), and translational move-
ent will impair the effectiveness of TDI techniques (24).
ome of these are overcome by strain imaging, and studies
re now appearing using speckle tracking, which shows clear
uperiority, particularly radial strain and torsion can also be
valuated (25–27).
onclusions
he reality is that not all patients implanted with CRT
evices improve and some worsen, and there is an impera-
ive to improve our selection procedures to prevent harm
eing done. This concept should not be dismissed lightly.
owever, it is certain that a combination of methodologies
ill need to be used, with magnetic resonance imaging to
dentify lateral wall scars, 2-dimensional speckle tracking to
nd the area of latest mechanical activation, and computed
omography scanning to assess venous anatomy before
mplantation. New large trials are required to properly test
his more targeted approach. This will mean progress for
ur patients and a more intelligent use of limited medical
esources. Unreasonable exhortations to follow current
uidelines should not be allowed to stifle developments that
ay refine those same guidelines for the overall benefit of
ur patients and society.
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